NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...
The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab ... IO Biotech is headquartered in Copenhagen, Denmark and has US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback